 MINNEAPOLIS, July 02, 2021 GLOBE NEWSWIRE -- CVRx, Inc. CVRx, a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, announced today the closing of its initial public offering of 8,050,000 shares of its common stock at a public offering price of 18.00 per share, which includes 1,050,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares, for total gross proceeds from the offering, before deducting the underwriting discount and other offering expenses payable by CVRx, of approximately 144.9 million. All of the shares of common stock were offered by CVRx. CVRxs common stock began trading on the Nasdaq Global Select Market on June 30, 2021, under the ticker symbol CVRX. 